BioCrea GmbH kündigt Teilnahme an drei internationalen Konferenzen mit dem Thema “On target with rapid acting antidepressants” an

Biocrea GmbH, der First-in-Class CNS Drug Discovery-Spezialist, gab heute bekannt, dass der Geschäftsführer, Dr. Tom Kronbach, das Thema “On target with rapid acting antidepressants” auf drei internationalen Life-Sciences-Konferenzen in den kommenden Monaten präsentieren wird.

Radebeul, Germany, September 24, 2014 – BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today announced that Chief Executive Officer, Dr. Tom Kronbach, will present at the following three international life sciences conferences over the coming months.

Dr. Tom Kronbach will be presenting “On target with rapid acting antidepressants (RAAD)” at:

The 14th Annual Biotech in Europe Forum, September 30 – October 1, 2014: Basel, Switzerland 
Corporate presentation on September 30, 2014 at 11:00-11:15 CET in the Lima room
The Neuroscience Panel
September 30, 2014 at 15:30-16:30 CET

European Partnering and Investment Conference (EPIC), October 2, 2014: London, UK
Corporate presentation on October 2, 2014 at 11:30 BST in the Maynard 1 room

Therapeutic Area Partnerships (TAP), November 19 - 21, 2014: Boston, USA
Date and time of presentation to be confirmed

“It is an exciting time to be presenting the BioCrea story and our lead program to three eminent international specialist audiences. In particular, we will focus on our advanced NMDA receptor 2B drug candidates for treatment-resistant depression,” said Dr. Tom Kronbach, CEO of BioCrea, in the run-up to the events.

For updates on these conferences please also visit our website:

About the 14th Annual Biotech in Europe Forum

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100 presenting companies.

About the EPIC Biotech Conference

An autumnal event for 2014 when we will once again be showcasing the best of UK and European biotechs in a one day format. Some 50-60 European and UK biotech companies will be presenting and are looking for partners, investment or services. Our audience will comprise 250 - 300 delegates from the pharma, biotech, investor, CRO and service sectors. Industry keynotes will set the tone for the day and partnering will take place all day as well as informal networking.

About the Therapeutic Area Partnerships (TAP)

A meeting for the sharpest minds in biopharma. Since its launch eight years ago, TAP has come to be regarded as the industry's premier biopharmaceutical partnering event. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in: Oncology, Cardiovascular, Neuroscience, Infectious Diseases, Anti-Inflammatory/Autoimmune Diseases, Advanced Therapies (Cellular and Gene Therapies, Rare Diseases and other high value and niche areas).
Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events.

About BioCrea

BioCrea, the Radebeul-based first-in-class drug discovery specialist validated through pharma partnerships, has established a number of programs in neurological and psychiatric disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimization approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease). For more information, please visit


Dr. Tom Kronbach
CEO, BioCrea GmbH
Tel.: +49 351 / 4043 3332
Fax: +49 351 / 4043 3216

Quelle: Pressemitteilung der BioCea GmbH vom 24.09.2014